The Celiac Disease Comprehensive Panel screens for celiac disease by measuring Tissue Transglutaminase (tTG) Antibody IgA and total IgA. If tTG IgA is positive, an Endomysial Antibody Screen IgA is added for confirmation. If IgA levels are low, tTG IgG is performed to ensure accurate detection. Doctors use this blood panel to identify gluten sensitivity, confirm diagnosis, and guide treatment for patients with suspected celiac disease.

The Celiac Disease Comprehensive Panel for Infants measures antibodies linked to gluten sensitivity and autoimmune activity. It includes tissue transglutaminase (tTG), deamidated gliadin peptide (DGP), and total IgA to support detection of early immune reactions. By identifying abnormal antibody patterns, this panel helps evaluate gluten intolerance, malabsorption, and celiac risk in infants.

The HLA (Human Leukocyte Antigen) Typing for Celiac Disease test is a genetic test that identifies specific HLA gene variants associated with an increased risk of developing celiac disease. Celiac disease is an autoimmune disorder triggered by the ingestion of gluten, a protein found in wheat, barley, and rye. This test aids in assessing the genetic predisposition to celiac disease.

The Celiac & Gluten Response Panel — Comprehensive provides an in-depth evaluation of gluten-related immune response, intestinal inflammation, and nutrient status. By measuring celiac-specific antibodies, total IgA, stool calprotectin, CRP, CBC, iron stores, vitamin D, B12, folate, and zinc, this panel offers a comprehensive view of how gluten exposure may affect immune activity, gut health, and nutritional balance.